BFRI (Biofrontera) Debt-to-Equity : 0.18 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Debt-to-Equity?

Biofrontera's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.67 Mil. Biofrontera's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.32 Mil. Biofrontera's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $5.53 Mil. Biofrontera's debt to equity for the quarter that ended in Sep. 2024 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biofrontera's Debt-to-Equity or its related term are showing as below:

BFRI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.27 Med: 0.13 Max: 2.71
Current: 0.18

During the past 5 years, the highest Debt-to-Equity Ratio of Biofrontera was 2.71. The lowest was -1.27. And the median was 0.13.

BFRI's Debt-to-Equity is ranked better than
60.82% of 827 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs BFRI: 0.18

Biofrontera Debt-to-Equity Historical Data

The historical data trend for Biofrontera's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Debt-to-Equity Chart

Biofrontera Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.27

0.06

1.13

Biofrontera Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial														2.71	1.13	-0.68	0.13	0.18

Competitive Comparison of Biofrontera's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biofrontera's Debt-to-Equity falls into.

Biofrontera Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biofrontera's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.595	+	0.804)	/	4.793
	=	1.13

Biofrontera's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.67	+	0.324)	/	5.53
	=	0.18

Biofrontera (NAS:BFRI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biofrontera Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biofrontera's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Presidential Way, Suite 330, Woburn, MA, USA, 01801

Website

https://www.biofrontera-us.com

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Executives

Heikki Lanckriet	director	C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler	officer: Chief Financial Officer	84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber	director	119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii	director	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman	director	5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge	director	21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera	10 percent owner	HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates	officer: Controller	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco	director, officer: Chief Financial Officer/COO	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert	director, officer: Chief Executive Officer	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801